1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Primary Hyperoxaluria Type 3: new trials by email Literature Review of Primary Hyperoxaluria Type 3 trials Research Report on Primary Hyperoxaluria Type 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function nedosiran - Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 | Phase 2 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 27 | 2022-02-22 | 2026-04-16 |
Hyperoxaluria, Primary (1) · Primary hyperoxaluria type 1 (1) · Primary hyperoxaluria type 2 (1)
Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genetic Diseases, Inborn (1) · Hyperoxaluria (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Nutritional and Metabolic Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
nedosiran (1)
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1)
Canada (1) · Germany (1) · Italy (1) · Japan (1) · Lebanon (1) · Poland (1) · Spain (1) · Turkey (Türkiye) (1) · United Arab Emirates (1) · United Kingdom (1) · United States (1)